On November 30th local time, Novo Nordisk USA announced that as part of its ongoing commitment to patient safety, the company is taking several additional legal actions to protect American patients and consumers from adulterated drugs claimed to contain semaglutide sold by two pharmacies, Wells Pharmaceuticals and Brooksville Pharmaceuticals.